ASPIRE: Assessing the Safety of Pregnancy In the CoRonavirus PandEmic
A nationwide prospective cohort study of pregnant women and their offspring during the COVID-19 pandemic. This study is being done to help understand the spread of COVID-19 infection among pregnant women and how an infection might affect the health and wellbeing of pregnant mothers and their babies.
ASPIRE is a prospective study of 10,000 women recruited in early pregnancy. Pregnant women between the gestational ages of 4-10 weeks are eligible to participate, including IVF, IUI or spontaneous conceptions. The four main elements of participation include the following:
- Sero-surveillance for COVID-19 antibodies throughout pregnancy using blood spot cards at home
- Symptom surveillance through mobile push notifications
- Questionnaires to report symptoms, obstetrical outcomes and newborn outcomes up to 18 months
- Release of medical records
This nationwide Society for Assisted Reproductive Technology (SART) initiative will be coordinated by the UCSF Core Research Team.
- All patients achieving pregnancy via IVF, IUI, SI and spontaneously, from April 30, 2020, through December 31st, 2020, are invited to participate in this study.
- Patient enrollment in the study is self-directed and voluntary.
- Local IRB approval is not required.
- Participation is completely voluntary.